A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

An Arizona veteran who learned he has ALS is exploring a new blood test that researchers at UCLA are studying.

Dear Doctor, I am negative, and she is positive, so I had another test, which proved that she did not have sickle cell disease, and so we went ahead and got married.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Natera ( ($NTRA) ) just unveiled an update. On December 4, 2025, Natera, Inc. completed its acquisition of Foresight Diagnostics, a cancer ...

A closeup look at colibactin’s structure reveals chemical motifs that guide its mutation-wreaking “warheads” to specific stretches of DNA.

Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando ...